Grifols’ EUR1.1 Billion Acquisition Of Biotest

Osborne Clarke has advised Grifols on the deal.

Grifols signed an agreement with the Hong Kong’s Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.

Once the agreement is consummated (it is subject to closing conditions), Grifols will indirectly hold 89.88% of Biotest’s voting rights and 44.94% of the total share capital. Grifols has also announced that it will make a Voluntary Tender Offer for the remaining Biotest shares.

Osborne Clarke’s international team was led by key client partner Tomás Dagá (Picture), who was supported by Óscar Calsamiglia, Núria Martin, Eduard Arruga, Miguel Lorán, Laura de la Cruz and Ignasi Bruguer in Spain, alongside Matthias Elser, Fabian Christoph and Sebastian Hack and Joachim Breithaupt in Germany, and by Andrew Saul and Matthew Edwards in the UK.

Involved fees earner: Eduard Arruga – Osborne Clarke; Joachim Breithaupt – Osborne Clarke; Ignasi Bruguer – Osborne Clarke; Oscar Calsamiglia – Osborne Clarke; Fabian Christoph – Osborne Clarke; Tomás Dágá – Osborne Clarke; Laura de la Cruz – Osborne Clarke; Matthew Edwards – Osborne Clarke; Matthias Elser – Osborne Clarke; Sebastian Hack – Osborne Clarke; Miguel Lorán – Osborne Clarke; Nuria Martin – Osborne Clarke; Andrew Saul – Osborne Clarke;

Law Firms: Osborne Clarke;

Clients: Grifols;

Author: Federica Tiefenthaler